150 related articles for article (PubMed ID: 22014569)
1. Resistance to EGFR-targeted therapy: a family affair.
Vlacich G; Coffey RJ
Cancer Cell; 2011 Oct; 20(4):423-5. PubMed ID: 22014569
[TBL] [Abstract][Full Text] [Related]
2. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
3. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.
Yonesaka K; Zejnullahu K; Okamoto I; Satoh T; Cappuzzo F; Souglakos J; Ercan D; Rogers A; Roncalli M; Takeda M; Fujisaka Y; Philips J; Shimizu T; Maenishi O; Cho Y; Sun J; Destro A; Taira K; Takeda K; Okabe T; Swanson J; Itoh H; Takada M; Lifshits E; Okuno K; Engelman JA; Shivdasani RA; Nishio K; Fukuoka M; Varella-Garcia M; Nakagawa K; Jänne PA
Sci Transl Med; 2011 Sep; 3(99):99ra86. PubMed ID: 21900593
[TBL] [Abstract][Full Text] [Related]
4. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
[TBL] [Abstract][Full Text] [Related]
5. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
7. Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI.
Yonesaka K; Tanaka K; Kitano M; Kawakami H; Hayashi H; Takeda M; Sakai K; Nishio K; Doi K; Nakagawa K
Oncogenesis; 2019 Sep; 8(10):54. PubMed ID: 31570699
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2.
Maurer CA; Friess H; Kretschmann B; Zimmermann A; Stauffer A; Baer HU; Korc M; Büchler MW
Hum Pathol; 1998 Aug; 29(8):771-7. PubMed ID: 9712416
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery.
Lee JC; Wang ST; Chow NH; Yang HB
Eur J Cancer; 2002 May; 38(8):1065-71. PubMed ID: 12008194
[TBL] [Abstract][Full Text] [Related]
10. Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer.
Klupp F; Sass M; Bergmann F; Khajeh E; Ghamarnejad O; Hassenpflug M; Mehrabi A; Kulu Y
Oncol Lett; 2021 Jun; 21(6):448. PubMed ID: 33868486
[TBL] [Abstract][Full Text] [Related]
11. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
Schoeberl B; Kudla A; Masson K; Kalra A; Curley M; Finn G; Pace E; Harms B; Kim J; Kearns J; Fulgham A; Burenkova O; Grantcharova V; Yarar D; Paragas V; Fitzgerald J; Wainszelbaum M; West K; Mathews S; Nering R; Adiwijaya B; Garcia G; Kubasek B; Moyo V; Czibere A; Nielsen UB; MacBeath G
NPJ Syst Biol Appl; 2017; 3():16034. PubMed ID: 28725482
[TBL] [Abstract][Full Text] [Related]
12. ErbB2 and ErbB3 receptors mediate inhibition of calcium-dependent chloride secretion in colonic epithelial cells.
Keely SJ; Barrett KE
J Biol Chem; 1999 Nov; 274(47):33449-54. PubMed ID: 10559227
[TBL] [Abstract][Full Text] [Related]
13. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
14. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Frogne T; Benjaminsen RV; Sonne-Hansen K; Sorensen BS; Nexo E; Laenkholm AV; Rasmussen LM; Riese DJ; de Cremoux P; Stenvang J; Lykkesfeldt AE
Breast Cancer Res Treat; 2009 Mar; 114(2):263-75. PubMed ID: 18409071
[TBL] [Abstract][Full Text] [Related]
15. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
16. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.
Fitzpatrick VD; Pisacane PI; Vandlen RL; Sliwkowski MX
FEBS Lett; 1998 Jul; 431(1):102-6. PubMed ID: 9684874
[TBL] [Abstract][Full Text] [Related]
17. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
Li Z; Mei Y; Liu X; Zhou M
Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
[TBL] [Abstract][Full Text] [Related]
18. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.
Baro M; Lopez Sambrooks C; Burtness BA; Lemmon MA; Contessa JN
Mol Cancer Ther; 2019 Nov; 18(11):2124-2134. PubMed ID: 31387891
[TBL] [Abstract][Full Text] [Related]
19. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]